Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / About EDRN / Scientific Components

Scientific Components

The components and projects that comprise the Early Detection Research Network.
  • Biomarker Development Laboratories

    Responsible for the development and characterization of new biomarkers or the refinement of existing biomarkers.

  • Biomarker Reference Laboratories

    Serve as a Network resource for clinical and laboratory validation of biomarkers, which includes technological development, quality control, refinement, and high throughput.

  • Clinical Validation Centers

    Conduct clinical and epidemiological research regarding the clinical application of biomarkers.

  • Data Management and Coordinating Center

    Coordinates the EDRN research activities, providing logistic support, and conducting statistical and computational research for data analysis, analyzing data for validation. Also responsible for EDRN common database development.

  • Informatics Center

    The Informatics Center supports EDRN's efforts through the development of software systems for information management. The center is at the NASA Jet Propulsion Laboratory at the California Institute of Technology.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.